Skip to content
logo-removebg-preview (2)
  • Home
  • Our Team
    • Board of Directors
    • Management
    • Join Our Team
    • Academic Collaboration
  • Areas of Focus
    • Scientific Approach
    • Therapeutic Areas
  • Pipeline
    • Development Pipeline
    • AIV001
    • AIV007
    • JEL Technology
  • Investor
    • News
    • Press Releases
    • Events
    • Partnerships
  • Contact
New Logo
  • Home
  • Our Team
  • Therapeutic Areas
  • Development Pipeline
  • Events
  • Partnerships
  • Contact

Archive for August 2023

AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors

By AiViva BioPharma | August 30, 2023

Costa Mesa, Calif., August 30, 2023 (GlobeNewswire) – AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Mr.…

Read More

Recent Posts

  • AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
  • AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
  • AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
  • AiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors
  • AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors

Recent Comments

No comments to show.
New Logo

1451 Quail Street, Suite 204
Newport Beach, CA  92660

New Logo

151 Kalmus Drive, Building C, Suite C-200
Costa Mesa, CA 92626

  • Home
  • Our Team
  • Therapeutic Areas
  • Development Pipeline
  • Events
  • Partnerships
  • Contact
  • Home
  • Our Team
  • Therapeutic Areas
  • Development Pipeline
  • Events
  • Partnerships
  • Contact

© 2026 AiViva BioPharma. All Rights Reserved.

GoDaddy Web Design
Scroll To Top